Clinical and structural remission rates increased annually and radiographic progression was continuously inhibited during a 3-year administration of tocilizumab in patients with rheumatoid arthritis: A multi-center, prospective cohort study by the Michinoku Tocilizumab Study Group

Objective: To evaluate the clinical and structural efficacy of tocilizumab (TCZ) during its long-term administration in patients with rheumatoid arthritis (RA). Methods: In total, 693 patients with RA who started TCZ therapy were followed for 3 years. Clinical efficacy was evaluated by DAS28-ESR and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Modern rheumatology 2016-11, Vol.26 (6), p.828-835
Hauptverfasser:	Hirabayashi, Yasuhiko, Munakata, Yasuhiko, Miyata, Masayuki, Urata, Yukitomo, Saito, Koichi, Okuno, Hiroshi, Yoshida, Masaaki, Kodera, Takao, Watanabe, Ryu, Miyamoto, Seiya, Ishii, Tomonori, Nakazawa, Shigeshi, Takemori, Hiromitsu, Ando, Takanobu, Kanno, Takashi, Komagamine, Masataka, Kato, Ichiro, Takahashi, Yuichi, Komatsuda, Atsushi, Endo, Kojiro, Murai, Chihiro, Takakubo, Yuya, Miura, Takao, Sato, Yukio, Ichikawa, Kazunobu, Konta, Tsuneo, Chiba, Noriyuki, Muryoi, Tai, Kobayashi, Hiroko, Fujii, Hiroshi, Sekiguchi, Yukio, Hatakeyama, Akira, Ogura, Ken, Sakuraba, Hirotake, Asano, Tomoyuki, Kanazawa, Hiroshi, Suzuki, Eiji, Takasaki, Satoshi, Asakura, Kenichi, Sugisaki, Kota, Suzuki, Yoko, Takagi, Michiaki, Nakayama, Takahiro, Watanabe, Hiroshi, Miura, Keiki, Mori, Yu
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - diagnostic imaging Arthritis, Rheumatoid - drug therapy Disease Progression Female Humans Joint destruction Long-term administration Male Middle Aged Prospective Studies Real clinical practice Remission Induction - methods Rheumatoid arthritis Tocilizumab Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!